Atezolizumab plus albumin paclitaxel-based regimens is an optional treatment for EGFR-mutant patients with SCLC transformation after EGFR-TKI

被引：0
|
作者：
Wang, J. [1 ]
Wang, Y. [2 ]
机构：
[1] Peking Univ Canc Hosp & Inst, Dept Thorac Med Oncol, Beijing, Peoples R China
[2] Peking Univ Canc Hosp, Thorac Oncol, Beijing Canc Hosp, Beijing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
32P
引用
收藏
页码：S58 / S59
页数：2
相关论文
共 50 条
  • [41] Factors affecting PS deterioration at the time of relapse after the first-line EGFR-TKI therapy in EGFR-mutant advanced NSCLC
    Tamura, Tomoki
    Hotta, Katsuyuki
    Gotoda, Hiroko
    Kato, Yuka
    Ichihara, Eiki
    Kubo, Toshio
    Tanimoto, Mltsune
    Kiura, Katsuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [42] Etoposide/platinum plus anlotinib for patients with transformed small-cell lung cancer from EGFR-mutant lung adenocarcinoma after EGFR-TKI resistance: a retrospective and observational study
    Ding, Jianghua
    Leng, Zhaohui
    Gu, Hong
    Jing, Xiang
    Song, Yun
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [43] EGFR-mutant NSCLC may remodel TME from non-inflamed to inflamed through acquiring resistance to EGFR-TKI treatment
    Chen, Qianqian
    Xia, Liliang
    Wang, Jingze
    Zhu, Shuxin
    Wang, Jing
    Li, Xing
    Yu, Yongfeng
    Li, Ziming
    Wang, Ying
    Zhu, Guanshan
    Lu, Shun
    LUNG CANCER, 2024, 192
  • [44] HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
    Gan, Jiadi
    Huang, Yihua
    Liao, Jun
    Pang, Lanlan
    Fang, Wenfeng
    ONCOTARGETS AND THERAPY, 2021, 14 : 5297 - 5307
  • [45] The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma
    Zhang, Qiuyi
    Ke, Ee
    Niu, Feiyu
    Deng, Wei
    Chen, Zhihong
    Xu, Chongrui
    Zhang, Xuchao
    Zhao, Ning
    Su, Jian
    Yang, Jinji
    Yan, Honghong
    Wu, Yilong
    Zhou, Qing
    ONCOTARGET, 2017, 8 (03) : 4994 - 5002
  • [46] Treatment outcomes of EGFR-TKI with or without locoregional brain therapy in advanced EGFR-mutant non-small cell lung cancer patients with brain metastases
    Linh, Do Mai
    Thinh, Tran Huy
    Hieu, Nguyen-Van
    Duc, Nguyen Minh
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2023, 27 (02): : 71 - 79
  • [47] Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer
    Zhang, Chen
    Cao, Honggang
    Cui, Yanan
    Jin, Shidai
    Gao, Wen
    Huang, Chenjun
    Guo, Renhua
    THORACIC CANCER, 2021, 12 (19) : 2574 - 2584
  • [48] Oral Vinorelbine Monotherapy in Patients with EGFR plus NSCLC after Failure of EGFR-TKI in First Line: A Prospective Study
    Kowalski, Dariusz
    Banna, Giuseppe Luigi
    Ramlau, Rodryg
    Ceresoli, Giovanni
    Camerini, Andrea
    Milanowski, Janusz
    Caruso, Michele
    Landreau, Philippe
    Vedovato, Jean-Claude
    Tang, Eng Huat
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1217 - S1218
  • [49] Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI
    Hata, Akito
    Katakami, Nobuyuki
    Yoshioka, Hiroshige
    Kaji, Reiko
    Masago, Katsuhiro
    Fujita, Shiro
    Imai, Yukihiro
    Nishiyama, Akihiro
    Ishida, Tadashi
    Nishimura, Yoshihiro
    Yatabe, Yasushi
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (11) : 1553 - 1559
  • [50] Role of T790M Mutation in EGFR-TKI Rechallenge for Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer
    Zhang, Qiu-Yi
    Ke, E-E
    Deng, Wei
    Niu, Fei-Yu
    Zhao, Ning
    Su, Jian
    Chen, Zhi-Hong
    Yang, Jin-Ji
    Xu, Chong-Rui
    Yan, Hong-Hong
    Wu, Yi-Long
    Zhou, Qing
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S271 - S271
12345